Touching Base Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett
Feb 9, 2024
Gene therapy updates for rare diseases by Intellia and Ultragenyx, Novo Holdings' acquisition of Catalent for $16.5B to keep up with drug demand, NanoString bankruptcy after patent infringement lawsuit, and an interview with Simon Barnett on advancing biotech's digitization and the intersection of machine learning and biophysics in structural biology.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 4min
Gene Therapy for Pediatric Neurodegenerative Disorders
03:54 • 7min
NanoString Files for Chapter 11 Bankruptcy
10:34 • 6min
Novo Nerve Niska's Acquisition of Cattlelin and Manufacturing Updates
16:20 • 4min
Interview with Simon Barnett, Research Director at Dimension
20:18 • 2min
Intersection of Machine Learning and Biophysics in Structural Biology
22:22 • 22min